Oppenheimer Raises Target on Alexion (ALXN) to $100 as Asfotase Alfa Data Looks Promising
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Price: $182.01 --0%
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Shares of recent momentum play Alexion Pharma (Nasdaq: ALXN) got a late-day boost Thursday after an intraday research note from Oppenheimer's Bret Holley. The analyst boosted his price target on Alexion shares from $89 to $100 and maintained an Outperform rating.
The report followed earlier results from Alexion's Phase 2 asfotase alfa study in adolescents and adults with HPP. Holley estimates the product could generate $1.1 billion in peak sales. He is expecting approval of asfotase alfa for infant and juvenile HPP during the second half of 2014 and approval for adults and adolescents shortly thereafter.
With Alexion shares up 0.95 percent to $91.07 at last check, the Oppenheimer analyst's new price target suggests potential upside of about 10 percent.
Visit our Analyst Ratings page to track all the market-moving analyst calls on shares of Alexion.
The report followed earlier results from Alexion's Phase 2 asfotase alfa study in adolescents and adults with HPP. Holley estimates the product could generate $1.1 billion in peak sales. He is expecting approval of asfotase alfa for infant and juvenile HPP during the second half of 2014 and approval for adults and adolescents shortly thereafter.
With Alexion shares up 0.95 percent to $91.07 at last check, the Oppenheimer analyst's new price target suggests potential upside of about 10 percent.
Visit our Analyst Ratings page to track all the market-moving analyst calls on shares of Alexion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
- Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
